Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 3:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 768 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hypertension, Ocular Clear all
Completed Not applicable Interventional Results available

Study Comparing the P200TE and the P200TxE in Glaucoma Patients

NCT03912584
View directory record Official record
Conditions
Glaucoma
Interventions
P200TE, P200TxE
Device
Lead sponsor
Optos, PLC
Industry
Eligibility
22 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2022 · Synced Oct 5, 2026, 3:36 PM EDT
Completed No phase listed Observational

Comparison of Two OCT Device RNFL and GCIPL Measurements in Mild, Moderate, and Severe Glaucoma

NCT07350304
View directory record Official record
Conditions
Glaucoma
Interventions
Optical Coherence Tomography
Diagnostic Test
Lead sponsor
Twin Cities Eye Consultants
Other
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Coon Rapids, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 5, 2026, 3:36 PM EDT
Completed Phase 2 Interventional

Safety and Tolerability Study of QLS-101 in Adolescents With Sturge-Weber Syndrome (SWS)-Related Glaucoma Due to Elevated Episcleral Venous Pressure (EVP)

NCT05495269
View directory record Official record
Conditions
Sturge-Weber Syndrome, Glaucoma, Ocular Hypertension
Interventions
QLS-101 ophthalmic solution, 2.0 %
Drug
Lead sponsor
Qlaris Bio, Inc.
Industry
Eligibility
12 Years to 19 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 20, 2025 · Synced Oct 5, 2026, 3:36 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Nutritional Supplements and Performance During Visual Field Testing (B3 Vitamin)

NCT03797469
View directory record Official record
Conditions
Visual Field Defect, Peripheral, Glaucoma, Open-Angle
Interventions
Vitamin B3, Pyruvate, Placebo
Dietary Supplement
Lead sponsor
Columbia University
Other
Eligibility
40 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 11, 2021 · Synced Oct 5, 2026, 3:36 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Micropulse Laser Trabeculoplasty (MLT) Versus Selective Laser Trabeculoplasty (SLT) for Treatment of Open Angle Glaucoma

NCT01956942
View directory record Official record
Conditions
Open Angle Glaucoma
Interventions
Micropulse Laser Trabeculoplasty, Selective Laser Trabeculoplasty
Device
Lead sponsor
David Belyea
Other
Eligibility
Not listed
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 13, 2023 · Synced Oct 5, 2026, 3:36 PM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy of Changing to DuoTrav in Patients Uncontrolled on Timolol

NCT01336569
View directory record Official record
Conditions
Glaucoma
Interventions
Travoprost 0.004%/timolol maleate 0.5% fixed combination
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2013 · Synced Oct 5, 2026, 3:36 PM EDT
Completed Phase 4 Interventional

Mechanism of Action of TRAVATAN 0.004% in Subjects With Glaucoma or Ocular Hypertension

NCT00061503
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
Travoprost
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Call For Details, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 5, 2008 · Synced Oct 5, 2026, 3:36 PM EDT
Completed Phase 3 Interventional Results available

Clinical Study Comparing Two Models of a Travoprost Intraocular Implant

NCT03868124
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
G2-TR intraocular implant containing travoprost, Sham surgery + active-comparator eye drops
Combination Product · Drug
Lead sponsor
Glaukos Corporation
Industry
Eligibility
18 Years and older
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Nov 29, 2024 · Synced Oct 5, 2026, 3:36 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of SPARC0912 and Reference0912 in Open Angle Glaucoma or Ocular Hypertension

NCT00947661
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
SPARC0912, Reference0912
Drug
Lead sponsor
Sun Pharma Advanced Research Company Limited
Industry
Eligibility
18 Years and older
Enrollment
578 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Oct 5, 2026, 3:36 PM EDT
Completed Phase 4 Interventional Results available

Study of Rhopressa® for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension in a Real-world Setting

NCT03808688
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
Netarsudil Ophthalmic Solution 0.02%
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
22
States / cities
Huntington Beach, California • Laguna Hills, California • Petaluma, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2020 · Synced Oct 5, 2026, 3:36 PM EDT
Completed Phase 1Phase 2 Interventional

Safety and Efficacy Trial to Treat Open-Angle Glaucoma or Ocular Hypertension

NCT01279083
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
DE-112, DE-112 Vehicle Solution, Timolol Maleate Solution
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Austin, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 17, 2012 · Synced Oct 5, 2026, 3:36 PM EDT
Completed Not applicable Interventional

Partnership for Glaucoma

NCT00672048
View directory record Official record
Conditions
Glaucoma
Interventions
Computer Tablet, Continuing Education Course, Continuing education
Other
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
721 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
2
States / cities
Birmingham, Alabama • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Oct 5, 2026, 3:36 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Intraocular Pressure (IOP) Changes Associated With Muslim Prayer Postural Changes

NCT00454025
View directory record Official record
Conditions
Glaucoma
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 30, 2013 · Synced Oct 5, 2026, 3:36 PM EDT
Active, not recruiting Phase 4 Interventional

Effect of Rhopressa on Intraocular Pressure (IOP) in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Post-SLT

NCT06865144
View directory record Official record
Conditions
Primary Open Angle Glaucoma or Ocular Hypertension
Interventions
Netarsudil ophthalmic solution 0.02%, Artificial tears
Drug
Lead sponsor
East Coast Institute for Research
Network
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 5, 2026, 3:36 PM EDT
Active, not recruiting No phase listed Observational

Impact of Glaucoma and Visual Field Loss on Life Space

NCT03673644
View directory record Official record
Conditions
Primary Open-angle Glaucoma
Interventions
Questionnaires
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 5, 2026, 3:36 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study to Compare Kowa OCT Bi-μ and the Optovue iVue 100

NCT03505567
View directory record Official record
Conditions
Glaucoma, Retinal Disease, Healthy
Interventions
KOWA OCT Bi-µ, Optovue iVue 100
Device
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Oct 5, 2026, 3:36 PM EDT
Recruiting Phase 1 Interventional

Evaluating ER-100 for Safety in People With Glaucoma or Non-Arteritic Anterior Ischemic Optic Neuropathy (Optic Nerve Conditions)

NCT07290244
View directory record Official record
Conditions
Open Angle Glaucoma (OAG), NAION( Non-arteritic Anterior Ischemic Optic Neuropathy)
Interventions
ER-100 epigenetic therapy
Genetic
Lead sponsor
Life Biosciences Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
4
States / cities
Glendale, California • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 5, 2026, 3:36 PM EDT
Completed Phase 2 Interventional

A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

NCT00326092
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
Brinzolamide/Timolol
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Nov 18, 2016 · Synced Oct 5, 2026, 3:36 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension

NCT00332384
View directory record Official record
Conditions
Ocular Hypertension
Interventions
brimonidine/timolol fixed combination
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
573 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated May 30, 2011 · Synced Oct 5, 2026, 3:36 PM EDT
Completed No phase listed Interventional Results available

Safety and Intraocular Lowering Effect of Delivery of Travoprost Evolute® in Subjects With Elevated Intraocular Pressure

NCT04962009
View directory record Official record
Conditions
Elevated Intraocular Pressure (IOP)
Interventions
Travoprost Evolute® (Travoprost Punctal Plug Delivery System), 166 ug
Combination Product
Lead sponsor
Mati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 5, 2026, 3:36 PM EDT
Completed Not applicable Interventional

Glaucoma Management in the African-Derived Developing World Using Trabeculoplasty

NCT02375009
View directory record Official record
Conditions
Glaucoma
Interventions
Selective laser trabeculoplasty
Procedure
Lead sponsor
West Virginia University
Other
Eligibility
30 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Jun 18, 2021 · Synced Oct 5, 2026, 3:36 PM EDT
Completed Phase 4 Interventional

Lumigan Versus Cosopt

NCT00273455
View directory record Official record
Conditions
Open-Angle Glaucoma
Interventions
bimatoprost 0.03%, dorzolamide 2%/timolol maleate 0.5% fixed combination, placebo
Drug
Lead sponsor
Pharmaceutical Research Network
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
3
States / cities
Louisville, Kentucky • Mt. Pleasant, South Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 19, 2008 · Synced Oct 5, 2026, 3:36 PM EDT
Completed Phase 2 Interventional

A Study of RO5093151 in Patients With Ocular Hypertension Or Open Angle Glaucoma

NCT01493271
View directory record Official record
Conditions
Hypertension, Glaucoma, Open-Angle
Interventions
Placebo, RO5093151
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
21 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
3
States / cities
Morrow, Georgia • High Point, North Carolina • Mt. Pleasant, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 5, 2026, 3:36 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Caffeine Consumption in Glaucoma Patients and Healthy Subjects

NCT03675412
View directory record Official record
Conditions
Glaucoma, Primary Open Angle
Interventions
Caffeine tablet
Dietary Supplement
Lead sponsor
Wills Eye
Other
Eligibility
18 Years to 90 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 5, 2026, 3:36 PM EDT